References
- Chan WH, Singh R, Feldman SR. Should the presence of psoriatic arthritis change how we manage psoriasis? J Dermatolog Treat. 2021;32(8):863–865.
- Santos G, Sousa LE, João AMBL. Exacerbation of recalcitrant cutaneous sarcoidosis with adalimumab—a paradoxical effect? A case report. An Bras Dermatol. 2013;88(6 suppl 1):26–28.
- Megna M, Ocampo-Garza SS, Potestio L, et al. New-onset psoriatic arthritis under biologics in psoriasis patients: an increasing challenge? Biomedicines. 2021;9(10):1482.
- Napolitano M, Balato N, Caso F, et al. Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study. Clin Exp Rheumatol. 2017;35(1):137–140.
- Gisondi P, Bellinato F, Targher G, et al. Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. Ann. Rheum. Dis. 2021.
- Wang Y, Zhang L, Yang M, et al. Development of a predictive model for screening patients with psoriasis at increased risk of psoriatic arthritis. Dermatol Ther. 2021. doi:10.1007/s13555-021-00663-0.